多发性硬化症患者血浆 salusin-α 和 salusin-β 水平升高。

Increased level of plasma salusin-α and salusin-β in patients with multiple sclerosis.

机构信息

Faculty of Medicine, Department of Physiology, University of Bozok, Yozgat, 66200, Turkey.

Faculty of Medicine, Department of Medical Biology, University of Bozok, Yozgat, 66200, Turkey.

出版信息

Mult Scler Relat Disord. 2019 May;30:76-80. doi: 10.1016/j.msard.2019.02.003. Epub 2019 Feb 5.

DOI:10.1016/j.msard.2019.02.003

PMID:30738876

Abstract

BACKGROUND

Multiple Sclerosis (MS) is a potentially progressive autoimmune disorder of the central nervous system. The pathology of MS is characterized by inflammation, demyelination, reactive gliosis and neuronal damage. Salusin-α and salusin-β have been shown to be widely expressed in many tissues, including the central nervous system. In our study, we investigated whether salusin-α and salusin-β peptides had a relation with inflammation and whether it is related to Relapsing-Remitting Multiple Sclerosis (RRMS) disease.

METHODS

Forty healthy controls and forty patients with RRMS were included in the study. Salusin-α and Salusin-β levels were measured by Enzyme-linked Immuno-Sorbent Assay (ELISA).

RESULTS

Salusin-α and salusin-β levels were high at a significant level in RRMS patients compared to healthy controls (p < 0.0001). We found a strong positive correlation between salusin-α and salusin-β levels (p < 0.0001, r = 0,9925).

CONCLUSION

In conclusion, we found that there was a relationship between salusin-α and salusin-β levels, and MS disease. Since RRMS is the first stage of MS and its most common type, it is important to perform biomarker studies in this period in terms of early planning of treatment. Although salusin-α and salusin-β levels increase in RRMS patients, further studies are needed to understand its relation with other neurological and inflammatory diseases to define it as a biomarker.

摘要

背景

多发性硬化症（MS）是一种潜在的进行性自身免疫性中枢神经系统疾病。MS 的病理学特征是炎症、脱髓鞘、反应性神经胶质增生和神经元损伤。Salusin-α 和 Salusin-β 已被证明广泛存在于许多组织中，包括中枢神经系统。在我们的研究中，我们调查了 Salusin-α 和 Salusin-β 肽是否与炎症有关，以及它是否与复发缓解型多发性硬化症（RRMS）疾病有关。

方法

本研究纳入了 40 名健康对照者和 40 名 RRMS 患者。通过酶联免疫吸附试验（ELISA）测量 Salusin-α 和 Salusin-β 水平。

结果

RRMS 患者的 Salusin-α 和 Salusin-β 水平显著升高（p<0.0001）。我们发现 Salusin-α 和 Salusin-β 水平之间存在强烈的正相关（p<0.0001，r=0.9925）。

结论

总之，我们发现 Salusin-α 和 Salusin-β 水平与 MS 疾病之间存在关系。由于 RRMS 是 MS 的第一阶段，也是最常见的类型，因此在这一时期进行生物标志物研究对于早期规划治疗非常重要。尽管 RRMS 患者的 Salusin-α 和 Salusin-β 水平升高，但仍需要进一步研究以了解其与其他神经和炎症性疾病的关系，以将其定义为生物标志物。